Regen BioPharma, Inc. (RGBP)

Regen BioPharma Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Revenue	0.24	0.24	0.24	0.24	0.24	0.17
Revenue Growth (YoY)	0%	0%	-	0.44%	37.57%	55.63%
Gross Profit	0.24	0.24	0.24	0.24	0.24	0.17
Selling, General & Admin	0.88	0.56	0.5	0.71	0.3	0.34
Research & Development	0.22	0.01	0.15	0.21	0.28	0.04
Operating Expenses	1.11	0.58	0.65	0.92	0.58	0.37
Operating Income	-0.87	-0.34	-0.42	-0.69	-0.34	-0.2
Interest Expense	-0.21	-0.21	-0.1	-0.06	-0.21	-0.37
Interest & Investment Income	-	-	-	-	0	0
Other Non Operating Income (Expenses)	0.36	-0.73	-0.15	1.9	3	-4.26
EBT Excluding Unusual Items	-0.72	-1.27	-0.67	1.16	2.45	-4.83
Gain (Loss) on Sale of Investments	-	-	-	-	0.03	-1.16
Legal Settlements	-	-	-	-	-	-0.8
Other Unusual Items	-	-	-	0	-0.03	0.02
Pretax Income	-0.72	-1.27	-0.67	1.16	2.44	-6.77
Net Income	-0.72	-1.27	-0.67	1.16	2.44	-6.77
Preferred Dividends & Other Adjustments	-	-	-	0.13	0.22	-
Net Income to Common	-0.72	-1.27	-0.67	1.02	2.23	-6.77
Net Income Growth	-	-	-	-52.67%	-	-
Shares Outstanding (Basic)	85	24	8	7	6	4
Shares Outstanding (Diluted)	85	24	8	7	6	4
Shares Change (YoY)	507.33%	186.14%	16.21%	12.79%	56.19%	113.61%
EPS (Basic)	-0.01	-0.05	-0.08	0.14	0.36	-1.68
EPS (Diluted)	-0.01	-0.05	-0.08	0.14	0.36	-1.68
EPS Growth	-	-	-	-59.25%	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-367.41%	-143.11%	-176.37%	-290.39%	-144.20%	-117.28%
Profit Margin	-302.54%	-538.76%	-282.49%	432.66%	945.59%	-3951.79%
EBIT	-0.87	-0.34	-0.42	-0.69	-0.34	-0.2
EBIT Margin	-	-143.11%	-176.37%	-290.39%	-144.19%	-117.28%
Revenue as Reported	0.24	0.24	0.24	0.24	0.24	0.17

Source: S&P Global Market Intelligence. Standard template. Financial Sources.